Cytosorbents Future Growth
Future criteria checks 3/6
Cytosorbents is forecast to grow earnings and revenue by 77.3% and 11.1% per annum respectively while EPS is expected to grow by 78.4% per annum.
Key information
77.3%
Earnings growth rate
78.43%
EPS growth rate
| Medical Equipment earnings growth | 16.4% |
| Revenue growth rate | 11.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 May 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jun 16
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
Narrative Update • Jun 02
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
Narrative Update • May 15
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.Narrative Update • Apr 27
CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.Narrative Update • Apr 11
CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).Narrative Update • Mar 28
CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.Narrative Update • Mar 12
CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.Narrative Update • Feb 26
CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).Narrative Update • Feb 09
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.Narrative Update • Jan 26
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).Narrative Update • Jan 10
CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.Narrative Update • Dec 26
CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).Narrative Update • Dec 12
CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.Analysis Article • Nov 13
Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...Analysis Article • Nov 08
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Aug 10
FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.Analysis Article • Aug 09
Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...Analysis Article • Jul 02
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
New Narrative • Apr 11
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Analysis Article • Jan 17
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...Analysis Article • Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...Analysis Article • Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...Analysis Article • Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 52 | 5 | N/A | N/A | 1 |
| 12/31/2027 | 47 | 2 | N/A | N/A | 1 |
| 12/31/2026 | 38 | -12 | N/A | N/A | 2 |
| 3/31/2026 | 37 | -12 | -11 | -10 | N/A |
| 12/31/2025 | 37 | -8 | -13 | -12 | N/A |
| 9/30/2025 | 37 | -10 | -10 | -10 | N/A |
| 6/30/2025 | 36 | -10 | -10 | -10 | N/A |
| 3/31/2025 | 35 | -16 | -14 | -13 | N/A |
| 12/31/2024 | 36 | -21 | -15 | -14 | N/A |
| 9/30/2024 | 30 | -20 | -19 | -18 | N/A |
| 6/30/2024 | 30 | -26 | -22 | -21 | N/A |
| 3/31/2024 | 31 | -28 | -24 | -23 | N/A |
| 12/31/2023 | 31 | -29 | -23 | -22 | N/A |
| 9/30/2023 | 37 | -23 | -22 | -21 | N/A |
| 6/30/2023 | 36 | -26 | -24 | -22 | N/A |
| 3/31/2023 | 35 | -31 | -30 | -23 | N/A |
| 12/31/2022 | 35 | -33 | -35 | -28 | N/A |
| 9/30/2022 | 36 | -41 | -36 | -28 | N/A |
| 6/30/2022 | 38 | -36 | -34 | -26 | N/A |
| 3/31/2022 | 41 | -29 | -24 | -20 | N/A |
| 12/31/2021 | 43 | -25 | -18 | -14 | N/A |
| 9/30/2021 | 44 | -16 | -12 | -10 | N/A |
| 6/30/2021 | 45 | -10 | -11 | -9 | N/A |
| 3/31/2021 | 43 | -9 | -7 | -5 | N/A |
| 12/31/2020 | 41 | -8 | -7 | -6 | N/A |
| 9/30/2020 | 36 | -11 | -10 | -9 | N/A |
| 6/30/2020 | 32 | -17 | -12 | -11 | N/A |
| 3/31/2020 | 28 | -18 | -17 | -16 | N/A |
| 12/31/2019 | 25 | -19 | N/A | -17 | N/A |
| 9/30/2019 | 24 | -21 | N/A | -15 | N/A |
| 6/30/2019 | 23 | -17 | N/A | -13 | N/A |
| 3/31/2019 | 23 | -19 | N/A | -13 | N/A |
| 12/31/2018 | 23 | -17 | N/A | -11 | N/A |
| 9/30/2018 | 21 | -15 | N/A | -9 | N/A |
| 6/30/2018 | 19 | -14 | N/A | -8 | N/A |
| 3/31/2018 | 17 | -10 | N/A | -7 | N/A |
| 12/31/2017 | 15 | -9 | N/A | -6 | N/A |
| 9/30/2017 | 14 | -11 | N/A | -7 | N/A |
| 6/30/2017 | 12 | -10 | N/A | -7 | N/A |
| 3/31/2017 | 11 | -11 | N/A | -7 | N/A |
| 12/31/2016 | 10 | -12 | N/A | -7 | N/A |
| 9/30/2016 | 8 | -9 | N/A | -8 | N/A |
| 6/30/2016 | 7 | -10 | N/A | -8 | N/A |
| 3/31/2016 | 6 | -5 | N/A | -8 | N/A |
| 12/31/2015 | 5 | -9 | N/A | -9 | N/A |
| 9/30/2015 | 4 | -17 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTSO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: CTSO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CTSO is expected to become profitable in the next 3 years.
Revenue vs Market: CTSO's revenue (11.1% per year) is forecast to grow slower than the US market (12.7% per year).
High Growth Revenue: CTSO's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:18 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| Danielle Antalffy | Leerink Partners LLC |